Journal of the American Society of Nephrology· 2017Q1
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
- 298citations
- Q1SCImago
- 2017year
Short summary
A randomized trial (BORTEJECT) found that bortezomib did not significantly prevent GFR decline in kidney transplant recipients with late antibody-mediated rejection (ABMR), showing no improvement in GFR, graft survival, or rejection markers over 24 months compared to placebo, and was associated with increased toxicity.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine